Par Drugs & Chem.

₹261 -0.9 | 0.3%

WEBSITE BSE:0 NSE : 18 May, 12:47

Market Cap ₹321 Cr.

Stock P/E 22.2

P/B 3.8

Current Price ₹261

Book Value ₹ 69.6

Face Value 10

52W High ₹325

Dividend Yield 0%

52W Low ₹ 178

Edit Ratio

Par Drugs & Chem. Research see more...

Overview Inc. Year: 1999Industry: Chemicals

Par Drugs And Chemicals Ltd is a reputable pharmaceutical company that operates in the healthcare industry. With a focus on manufacturing and marketing a wide range of high-quality pharmaceutical products, Par Drugs And Chemicals has established itself as a trusted name in the market. The company adheres to stringent quality standards and employs advanced manufacturing processes to ensure the effectiveness and safety of their medications. Par Drugs And Chemicals offers an extensive portfolio of medicines across various therapeutic areas, including cardiovascular, respiratory, gastrointestinal, and central nervous system disorders. They also produce generic drugs, catering to the needs of a diverse customer base. The company's commitment to innovation and research enables them to introduce new and improved pharmaceutical formulations. Par Drugs And Chemicals Ltd is dedicated to improving healthcare outcomes by providing affordable and accessible medicines. Through their strong distribution network, they ensure timely availability of their products across different regions. Their customer-centric approach, combined with their expertise in the pharmaceutical domain, positions them as a reliable and valued partner in the healthcare sector.

Par Drugs & Chem. Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Par Drugs & Chem. Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	17	22	24	25	23	24	23	26	24	23
Other Income	0	0	0	0	0	0	0	0	0	-0
Total Income	17	22	24	25	23	25	23	26	24	23
Total Expenditure	13	18	20	19	20	19	19	19	19	17
Operating Profit	4	5	4	6	3	5	4	7	5	6
Interest	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	3	4	3	5	2	5	3	7	5	5
Provision for Tax	1	1	1	1	1	1	1	2	1	1
Profit After Tax	2	2	2	4	2	3	2	5	3	4
Adjustments	0	0	0	0	0	0	-0	0	0	0
Profit After Adjustments	2	2	2	4	2	3	2	5	3	4
Adjusted Earnings Per Share	1.7	2	1.9	3	1.5	2.8	2	4	2.8	3

Par Drugs & Chem. Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	19	27	33	33	49	42	46	56	61	75	96	96
Other Income	0	0	0	0	0	0	0	0	0	0	0	0
Total Income	19	27	33	33	49	42	46	56	61	75	96	96
Total Expenditure	16	20	26	26	40	34	38	46	45	59	78	74
Operating Profit	3	7	8	7	9	8	8	10	16	16	18	22
Interest	1	4	4	4	3	2	2	1	1	0	0	0
Depreciation	1	2	2	3	3	3	3	3	3	3	3	4
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	2	0	0	0
Profit Before Tax	1	1	1	1	3	3	3	6	15	13	15	20
Provision for Tax	0	0	0	1	1	1	1	1	3	3	4	5
Profit After Tax	1	1	1	0	2	2	3	5	12	9	11	14
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	1	1	1	0	2	2	3	5	12	9	11	14
Adjusted Earnings Per Share	0	0	1.6	0.8	3.4	2.8	2.8	3.9	9.4	7.5	9.2	11.8

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	28%	20%	18%	18%
Operating Profit CAGR	13%	22%	18%	20%
PAT CAGR	22%	30%	41%	27%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	37%	62%	39%	NA%
ROE Average	17%	20%	17%	13%
ROCE Average	23%	25%	20%	15%

Par Drugs & Chem. Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	15	16	17	17	19	21	29	41	52	60	71
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	24	25	21	16	14	13	6	5	4	0	0
Other Non-Current Liabilities	1	2	2	2	3	3	4	4	4	4	4
Total Current Liabilities	12	18	19	22	20	17	12	11	16	15	14
Total Liabilities	53	61	59	58	56	54	51	60	76	79	89
Fixed Assets	43	47	45	43	42	39	36	34	30	34	38
Other Non-Current Assets	0	1	1	1	1	1	1	2	5	1	1
Total Current Assets	9	14	13	15	14	14	14	24	41	44	49
Total Assets	53	61	59	58	56	54	51	60	76	79	89

Par Drugs & Chem. Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	0	0	1	0	1	0	0	0	7	21	16
Cash Flow from Operating Activities	3	5	9	7	9	5	3	8	12	8	13
Cash Flow from Investing Activities	-24	-6	-0	-0	-2	-1	-0	-1	0	-3	-7
Cash Flow from Financing Activities	21	2	-9	-5	-8	-4	-3	1	2	-10	-0
Net Cash Inflow / Outflow	-0	1	-1	1	-1	0	-0	7	14	-5	6
Closing Cash & Cash Equivalent	0	1	0	1	0	0	0	7	21	16	22

Par Drugs & Chem. Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	1.67	1.34	1.64	0.78	3.42	2.82	2.8	3.87	9.44	7.49	9.21
CEPS(Rs)	3.37	5.36	5.96	5.69	8.64	8.63	6.19	6.12	11.73	10.15	11.84
DPS(Rs)	0	0	0	0	0	0	0	2.5	0	1.25	0
Book NAV/Share(Rs)	17.93	19.27	20.88	21.49	24.91	28.17	32.4	33.01	42.44	48.66	57.9
Core EBITDA Margin(%)	16.52	26.97	22.46	21.61	17.35	16.53	15.49	14.86	23.18	19.16	16.81
EBIT Margin(%)	11.59	19.02	15.56	13.76	11.66	10.15	9.92	10.68	22.25	15.51	14.04
Pre Tax Margin(%)	7.19	4.42	3.68	3.03	6.53	5.35	6.21	9.43	21.32	14.97	13.92
PAT Margin (%)	4.82	2.65	2.67	1.27	3.79	3.14	4.74	7.5	16.81	10.86	10.46
Cash Profit Margin (%)	9.75	10.6	9.68	9.23	9.57	9.59	10.47	11.85	20.89	14.73	13.45
ROA(%)	2.21	1.27	1.48	0.72	3.24	2.77	4.78	8.56	17.01	11.88	13.53
ROE(%)	9.76	7.21	8.18	3.69	14.75	10.63	11.35	13.68	25.02	16.44	17.29
ROCE(%)	5.98	10.18	9.92	9.36	12.34	11.19	12.41	15.56	28.68	21.85	23.2
Receivable days	70.05	76.88	83.87	81.71	57.97	63.27	59.42	59.99	65.58	66.5	59.7
Inventory Days	69.55	46.37	40.95	52.42	35.81	30.27	28.81	20.71	15.63	16.58	17
Payable days	3859.72	0	157.06	184.49	123.17	132.8	96.78	85.91	107.79	110.04	84.87
PER(x)	0	0	0	0	0	0	0	4.07	6.56	21.33	15.2
Price/Book(x)	0	0	0	0	0	0	0	0.48	1.46	3.28	2.42
Dividend Yield(%)	0	0	0	0	0	0	0	7.94	0	0.78	0
EV/Net Sales(x)	2.17	1.69	1.24	1.15	0.68	0.74	0.35	0.32	1.04	2.4	1.57
EV/Core EBITDA(x)	13.12	6.26	5.48	5.3	3.91	3.91	1.93	1.89	3.91	10.97	8.13
Net Sales Growth(%)	-0.39	46.07	21.77	0.05	46.6	-13.1	9.31	20.56	8.78	23.58	27.54
EBIT Growth(%)	-14.77	139.7	-0.39	-11.5	24.17	-13.27	6.59	29.14	126.48	-14.39	15.62
PAT Growth(%)	-19.78	-19.66	22.48	-52.42	338.07	-17.55	64.83	89.76	143.68	-20.65	23.02
EPS Growth(%)	-19.78	-19.66	22.48	-52.42	338.05	-17.55	-0.67	38.19	143.68	-20.65	23.02
Debt/Equity(x)	2.08	2.37	1.92	1.77	1.29	1.1	0.4	0.15	0.16	0	0
Current Ratio(x)	0.81	0.75	0.68	0.66	0.69	0.83	1.14	2.23	2.58	2.93	3.53
Quick Ratio(x)	0.51	0.56	0.47	0.41	0.49	0.59	0.79	1.96	2.39	2.61	3.15
Interest Cover(x)	2.63	1.3	1.31	1.28	2.27	2.11	2.68	8.55	23.93	28.97	114.21
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0.31	0.11	0	0

Par Drugs & Chem. Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	73.98	74.21	74.21	74.21	74.21	74.21	74.21	74.21	74.21	74.21
FII	0	0	0	0	0	0	0	0	0.07	0.07
DII	0	0.05	0.12	0	0	0	0	0	0	0.05
Public	26.02	25.75	25.67	25.79	25.79	25.79	25.79	25.79	25.73	25.68
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	0.91	0.91	0.91	0.91	0.91	0.91	0.91	0.91	0.91	0.91
FII	0	0	0	0	0	0	0	0	0	0
DII	0	0	0	0	0	0	0	0	0	0
Public	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32	0.32
Others	0	0	0	0	0	0	0	0	0	0
Total	1.23	1.23	1.23	1.23	1.23	1.23	1.23	1.23	1.23	1.23

Pros

Company has delivered good profit growth of 40% CAGR over last 5 years
Debtor days have improved from 110.04 to 84.87days.
Company is almost debt free.

Cons

Stock is trading at 3.8 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.